Biotechnology

DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative

NEW YORK, May 6, 2021 /PRNewswire/ -- DarwinHealth, a New York City-based biotechnology company, today announced a scientific research collaboration with Bristol-Myers Squibb Company (NYSE: BMY).  The research collaboration, theNovel Cancer Target Initiative (NCTI), employs quantitative systems b...

2021-05-06 20:31

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines

SHANGHAI and HONG KONG, May 6, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolog...

2021-05-06 11:28 664

CSafe Global Providing Thermal Protection for COVID-19 Vaccine Shipments from BioNTech Facility

The tailor-made double-wall VIP insulated shipper provides 10+ days of temperature protection for vaccine shipments from BioNTech's facility with minimal dry ice. DAYTON, Ohio, May 5, 2021 /PRNewswire/ -- CSafe Global, the innovation leader in active, passive parcel and cell and gene temperature...

2021-05-05 20:00 769

Cellares Raises $82M To Solve The Biggest Hurdles In Cell Therapy Manufacturing

Decheng Capital and Eclipse Ventures lead Series B round, bringing total funding to over$100 million SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ -- Cellares Corporation , a life sciences technology company that automates cell therapy manufacturing, today announced it has secured$82 mil...

2021-05-05 18:00 870

Warning about potential impacts on humanity through embryo gene editing

SINGAPORE, May 5, 2021 /PRNewswire/ -- A global conference on human fertility has been warned of huge societal and ethical challenges regulating advances in gene editing in assisted reproduction. Speaking at the 10th Congress of the Asian Pacific Initiative of Reproduction (ASPIRE), DrCatherin...

2021-05-05 16:38 743

CNN's Saved by the Future meets the innovators transforming the healthcare industry

HONG KONG, May 5, 2021 /PRNewswire/ -- In the latest episode of CNN's 'Saved by the Future', hostNicki Shields  meets the doctors, innovators and engineers working to develop the next generation of healthcare technology. 

2021-05-05 10:47 817

Ascletis Announces Positive Phase IIa HBV Results on Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)

HANGZHOU and SHAOXING, China, May 5, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) today announces the positive Phase IIa clinical results of ASC22 (Envafolimab), which is a first-in-class, subcutaneously administered PD-L1 antibody for chronic hepatitis B (CHB) functional cure. ASC2...

2021-05-05 08:30 948

IVM-MS2, 'The Most Compact All-in-One IntraVital Two-Photon Microscopy System in the World'

IVIM Technology, Inc. has released the most compact all-in-one intravital two-photon microscope, "IVM-MS2." IVIM Technology, Inc. is the world's first start-up that commercializes all-in-one integrated intravital microscopy equipment. Our equipment uses innovative intravital microscopy (IVM) tech...

2021-05-03 23:47 1074

Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study

China to Join Galmed's Phase 3 ARMOR Registrational Study for the Treatment of NASH & Fibrosis TEL AVIV, Israel, May 3, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory di...

2021-05-03 20:30 2776

BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction

VANCOUVER, BC, May 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (CSE: BIOV.CN) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "Company") announced today that it has signed the definitive exclusive bioproduction agreement ("Agreement") with BioElpida S.A.S. ("BioElpida") of Lyon,Franc...

2021-05-03 20:00 1497

Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study

82 Patient Pivotal cohort expected to commence in second half of 2021 BEDMINSTER, N.J. and SINGAPORE, April 30, 2021 /PRNewswire/ -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors...

2021-04-30 18:00 1134

BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH(R) Diagnostic

Commercial trademark application FILED for CoviDTH® diagnostic cancer vaccine platform patent coverageexpanded to NOW include over 12 tumor types VANCOUVER, B.C., April 29, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "the Company"), the world ...

2021-04-29 20:56 1641

Artificial Intelligence helps IVF patients avoid invasive embryo genetic testing

SAN FRANCISCO, April 29, 2021 /PRNewswire/ -- Life Whisperer, the fertility arm of AI healthcare company Presagen, has made a significant breakthrough in using artificial intelligence to non-invasively help embryologists rank and select genetically healthy embryos in IVF. Currently, PGT-A geneti...

2021-04-29 19:47 840

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

SHANGHAI and HONG KONG, April 29, 2021 /PRNewswire/ -- With the official release and implementation ofthe Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global innovative medicines in mainland China. Recently, the global first-in-class selective inhibitor of n...

2021-04-29 08:34 1310

Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration

SAN FRANCISCO and SUZHOU, China, April 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...

2021-04-29 08:00 2637

Novaliq Announces More than 50% Patients Enrolled in CyclASol® Phase 3 Dry Eye Disease Trial ESSENCE-2

- Topline results expected in 2nd half 2021; 475 out of a 834 target patients randomized in ESSENCE-2 - Enrollment for 12-month safety extension trial (ESSENCE-2 OLE) completed - Phase 2B/3 Trial ESSENCE-1 Published in Cornea: The Journal of Cornea and External Disease HEIDELBERG, Germany and C...

2021-04-28 20:00 716

CROs dMed and Clinipace Merge to Accelerate Customer Success

SHANGHAI and MORRISVILLE, N.C., April 28, 2021 /PRNewswire/ -- dMed Global, a full-service Clinical Contract Research Organization (CRO) based inShanghai, China, and Clinipace Incorporated, a full-service Clinical CRO with headquarters inNorth Carolina, USA, announced today that the two companies...

2021-04-28 20:00 1161

Turn Biotechnologies completes latest round of funding

Silicon Valley investor Khosla Ventures joins esteemed group of global investors backing Turn MOUNTAIN VIEW, Calif., April 28, 2021 /PRNewswire/ -- Turn Biotechnologies, a company developing novel RNA medicines for untreatable age-related conditions, today announced that it has closed its latest...

2021-04-28 19:50 1228

DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone

SALT LAKE CITY and TOKYO, April 27, 2021 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has c...

2021-04-27 09:23 1412

EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology

PROVIDENCE, R.I., April 27, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces the publication"Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs" inFrontiers in Immunology. This research highlights Tregitopes as a promising therapy for allergy. Administrati...

2021-04-27 09:00 1345
12345 ... 92